Abstract: The present invention, as disclosed herein, provides an isolated peptide, and a composition or material comprising a hydrogel, for the delivery of an active agent. The hydrogel comprises one or more isolated peptides and an active agent encapsulated in the hydrogel. The hydrogel is at least partially in a ?-sheet conformation. Further provided are a method for the encapsulation of an active agent in a hydrogel, a method for treating or diagnosing a condition or disease in a subject in need thereof.
Type:
Grant
Filed:
June 30, 2021
Date of Patent:
July 16, 2024
Assignee:
NANYANG TECHNOLOGICAL UNIVERSITY
Inventors:
Ali Gilles Tchenguise Miserez, Shu Hui Hiew, Chor Yong Tay, Jun Kit Wang
Abstract: The present disclosure provides CAPN5 substrates and CAPN5 inhibitors, nucleic acids encoding CAPN5 substrates or CAPN5 inhibitors, methods to deliver CAPN5 substrate or CAPN5 inhibitor agents to the eye, and methods of identifying inhibitors of CAPN5.
Type:
Grant
Filed:
October 2, 2017
Date of Patent:
May 14, 2024
Assignee:
UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventors:
Vinit B. Mahajan, Alexander G. Bassuk, Diana F. Colgan, Gabriel Velez, Kellie Schaefer, Marcus Toral, Shu Wu, Lokesh Gakhar
Abstract: A compound of formula (1) R1—Wm—Xn-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp—Zq—R2, wherein AA1 is Phe; AA2 is Trp; AA3 is selected from Met, Leu and lie; AA4 is selected from Lys, Arg and Gln; AA5 is Arg; AA6 is Lys; AA7 is selected from Arg, Lys and His; AA8 is selected from Val, Ile, Leu and Met; and AA9 is Pro. The compound is useful in the treatment and/or care of the skin, hair, nails and/or mucous membranes, in particular for improving the barrier function of the skin, for energizing the skin and as an anti-aging agent.
Type:
Grant
Filed:
June 5, 2018
Date of Patent:
February 13, 2024
Assignee:
LUBRIZOL ADVANCED MATERIALS, INC.
Inventors:
Raquel Delgado Gonzalez, Núria Almiñana Domènech, Consuelo García Hernández, Mauricio Valerio Santiago, Antonio Ferrer Montiel, Wim Van Den Nest, Catalina Rodríguez Bielsa
Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.
Abstract: The present invention provides compounds of formula (I) wherein X1, X2, R1 to R6 and A are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by bacteria.
Type:
Grant
Filed:
April 19, 2019
Date of Patent:
November 21, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Konrad Bleicher, Daniella Cheang, Patrick Di Giorgio, Patrizio Mattei, Petra Schmitz, Theodor Stoll
Abstract: The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.
Abstract: Modified hum1.an factor VIII polypeptides with enhanced factor VIII activity are described. In some embodiments, the modified human factor VIII polypeptides comprise one or more amino acid substitutions at positions A20, T21, P57, L69, I80, L178, R199, H212, I215, R269, I310, L318, S332, R378, I610 and/or I661. Such polypeptides and viral vectors encoding such polypeptides may be used for treatment of FVIII deficiencies, such as hemophilia A.
Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptoid oligomers are prepared as modulators of androgen receptor (AR), and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with unwanted or aberrant AR activity. The present peptoid oligomers are particularly valuable for the treatment of subjects with cancer.
Type:
Grant
Filed:
March 28, 2018
Date of Patent:
September 26, 2023
Assignee:
NEW YORK UNIVERSITY
Inventors:
Kent Kirshenbaum, Paul Michael Levine, Michael John Garabedian, Justin M. Holub
Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
Type:
Grant
Filed:
January 23, 2020
Date of Patent:
June 13, 2023
Assignee:
Allegro Pharmaceuticals, LLC
Inventors:
Michael John Mackel, John Y. Park, Hampar L. Karageozian, Vicken H. Karageozian
Abstract: The present disclosure relates to glucagon-like peptide-1 receptor (GLP-1R) agonists and methods of treating or preventing allergic inflammation and/or methods of treating or preventing respiratory syncytial virus (RSV) infection.
Abstract: The present disclosure provides a polypeptide conjugates comprising GLP-1 receptor agonist and a peptide linker, and pharmaceutical compositions comprising the same. Methods of using such for treating diseases are also provided.
Abstract: An ultrasound-assisted simulated digestion method of a milk protein active peptide and an application thereof in health foods, pertaining to the technical field of intensive processing of dairy products and preparation of health foods. The method firstly employs ultrasonic pretreatment of casein and ?-lactoglobulin, followed by enzymatic hydrolysis with a protease to prepare casein and ?-lactoglobulin polypeptide, and traces the activity of the polypeptide by simulating gastrointestinal digestion, and then simulates absorption by intestinal epithelial cells with Caco-2 cells, to characterize a highly active milk protein polypeptide digested by the gastrointestinal tract and absorbed by the Caco-2 cells simulating absorption by the inner wall of the small intestine. The method has identified five such highly active milk protein polypeptides.
Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
Type:
Grant
Filed:
April 8, 2019
Date of Patent:
November 22, 2022
Assignee:
Second Genome, Inc.
Inventors:
Cristina N. Butterfield, Daniela Keilberg, Andrew W. Goodyear, Andrew W. Han
Abstract: The specificity of CD4+ TH responses of German cockroach (Bla g) antigens, and whether differences exist in magnitude or functionality as a function of disease severity, is disclosed. Also disclosed are novel German cockroach allergens and epitopes.
Type:
Grant
Filed:
May 13, 2016
Date of Patent:
November 22, 2022
Assignee:
La Jolla Institute for Allergy and Immunology
Abstract: An object of the present invention is to provide an effective and safe medicament having effects for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by administration of an anti-malignant tumor agent, oxaliplatin, in a human cancer patient receiving an anti-malignant tumor treatment with oxaliplatin. There is provided a medicament for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by oxaliplatin in an anti-malignant tumor treatment consisting of repetition of a single cycle comprising intravenous administration of oxaliplatin to a human cancer patient and following drug withdrawal, which contains thrombomodulin for intravenously administering 0.06 mg/kg of thrombomodulin once per said single cycle of the treatment on the first day of each said cycle as an active ingredient.
Abstract: Synthetic nanostructures, polypeptides that are useful, for example, in making synthetic nanostructures, and methods for using such synthetic nanostructures are disclosed herein.
Type:
Grant
Filed:
May 31, 2019
Date of Patent:
November 1, 2022
Assignee:
University of Washington
Inventors:
David Baker, Jacob B. Bale, Neil P. King, William H. Sheffler, Daniel Ellis
Abstract: The present invention relates to recombinant binding proteins comprising one or more designed ankyrin repeat domains with binding specificity for coronavirus spike proteins, nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of coronavirus diseases, particularly diseases caused by SARS-CoV-2.
Type:
Grant
Filed:
May 6, 2021
Date of Patent:
October 11, 2022
Assignee:
MOLECULAR PARTNERS AG
Inventors:
Patrick Amstutz, Valerie Perrine Calabro, Marcel Walser
Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
Type:
Grant
Filed:
April 2, 2019
Date of Patent:
September 27, 2022
Assignee:
BICYCLETX LIMITED
Inventors:
Nicholas Keen, Kevin McDonnell, Peter Park, Punit Upadhyaya, Gemma Mudd
Abstract: The present invention relates to the determination of the level of marker peptides in a sample derived from a bodily fluid of a subject presenting with non-specific complaints.
Type:
Grant
Filed:
September 11, 2017
Date of Patent:
August 2, 2022
Assignee:
B.R.A.H.M.S GMBH
Inventors:
Joachim Struck, Christian Nickel, Roland Bingisser, Sven Giersdorf, Oliver Hartmann
Abstract: The present invention relates to a substrate for transglutaminase comprising a peptide having from 3 to 15 amino acids and comprising the amino acid sequence X?4X?3X?2X?1QX+1X+2X+3X+4, bound to a first molecule.